Serena Sophia Rudy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Serena Sophia Rudy has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Alexel Jesus Burgara-Estrella
Department of Research in Physics, University of Sonora, Blvd. Luis Donaldo Colosio, S/N, Hermosillo 83000, Mexico
1 shared publication - Ana María Guzmán Partida
Center for Research in Food and Development, Food Science Research Group, Gustavo Enrique Astiazaran Rosas 46, Hermosillo 83304, Sonora, Mexico
1 shared publication - Aracely Angulo-Molina
Universidad de Sonora
1 shared publication - Daniel Fernández-Quiroz
Departamento de Ingeniería Química y Metalurgia, Universidad de Sonora, Blvd. Luis Encinas y Rosales S/N, Col. Centro, Hermosillo 83000, Sonora, Mexico
1 shared publication - Erika Silva-Campa
Universidad de Sonora
1 shared publication - Jorge Jimenez-Canale
Universidad de Sonora
1 shared publication
Latest Publications
- Open Access
- 9 October 2025
- Published by MDPI AG in Nanomaterials
- Vol. 15 (19) , 1538
Chitosan-graft-poly(N-vinylcaprolactam) Nanoparticles Containing Crotalus atrox Snake Venom: Biological and Physicochemical Characterization
The development of snake venom-loaded nanobiosystems based on smart biopolymers represents a promising therapeutic approach in several biomedical research fields. Specifically, the western diamondback rattlesnake (Crotalus atrox) contains various bioactive peptides and proteins with reported antitumor activity. This research aimed to establish a simplistic, facile and straightforward protocol for preparing chitosan-g-poly(N-vinylcaprolactam) nanoparticles containing C. atrox venom for potential use as a therapeutic nanocarrier against breast carcinoma cell lines. Herein, the physicochemical properties of venom-loaded nanoparticles were evaluated by FTIR, DLS, and SDS-PAGE. Also, the biological properties of both C. atrox venom and Cs-Venom NPs such as hemagglutination and hemolysis activity were evaluated in vitro. Finally, we evaluated their cytotoxic activity against two breast carcinoma cell lines (T-47D and MDA-MB-231). The most suitable formulation exhibited a hydrodynamic size of 222 nm, a ζ-potential of 42.0 mV and an encapsulation efficiency of 88.6%. C. atrox venom exhibited hemagglutination at concentrations >15 µg/mL but, no hemagglutination or hemolysis was observed for the CS-Venom NPs. Lastly, the IC50 of Cs-Venom NPs was determined for the T-47D and MDA-MB-231 cell lines, at 61.7 and 59.0 µg/mL, respectively. Thus, Cs-Venom NPs exhibit promising properties that can be considered a feasible alternative for developing controlled-release therapeutic systems.
- 9 October 2025
- Published by MDPI AG in Nanomaterials
- Vol. 15 (19) , 1538
Open AccessChitosan-graft-poly(N-vinylcaprolactam) Nanoparticles Containing Crotalus atrox Snake Venom: Biological and Physicochemical Characterization
The development of snake venom-loaded nanobiosystems based on smart biopolymers represents a promising therapeutic approach in several biomedical research fields. Specifically, the western diamondback rattlesnake (Crotalus atrox) contains various bioactive peptides and proteins with reported antitumor activity. This research aimed to establish a simplistic, facile and straightforward protocol for preparing chitosan-g-poly(N-vinylcaprolactam) nanoparticles containing C. atrox venom for potential use as a therapeutic nanocarrier against breast carcinoma cell lines. Herein, the physicochemical properties of venom-loaded nanoparticles were evaluated by FTIR, DLS, and SDS-PAGE. Also, the biological properties of both C. atrox venom and Cs-Venom NPs such as hemagglutination and hemolysis activity were evaluated in vitro. Finally, we evaluated their cytotoxic activity against two breast carcinoma cell lines (T-47D and MDA-MB-231). The most suitable formulation exhibited a hydrodynamic size of 222 nm, a ζ-potential of 42.0 mV and an encapsulation efficiency of 88.6%. C. atrox venom exhibited hemagglutination at concentrations >15 µg/mL but, no hemagglutination or hemolysis was observed for the CS-Venom NPs. Lastly, the IC50 of Cs-Venom NPs was determined for the T-47D and MDA-MB-231 cell lines, at 61.7 and 59.0 µg/mL, respectively. Thus, Cs-Venom NPs exhibit promising properties that can be considered a feasible alternative for developing controlled-release therapeutic systems.